, San Jose, USA.
Pharm Res. 2020 Feb 13;37(3):54. doi: 10.1007/s11095-020-2776-3.
A proposed treatment using dual-peptide ligand masks, that are functional extensions to existing analogous mammalian immune system structures, to bind to cancer cell surface proteins and stop mutating cancers that could evade presently used engineered immune cell therapies. One treatment injects the dual-peptide ligand masks into the blood stream of patients, and another treatment injects the dual-peptide ligand masks into localized cancers to bind to cancer cell surface proteins. The mammalian immune system has long used analogous, but more complex structures called pentraxins to physically link various types of pathogens to immune cells for neutralization. This treatment approach offers potential advantages in increased binding adaptability to mutations in the surface proteins of cancer cells, and potentially lower treatment cost compared to engineered immune cell treatments against cancer, especially against mutating cancer cells, even compared to extremely specific and costly monoclonal antibody treatments or engineered T cell treatments.
一种使用双肽配体掩蔽物的治疗方法，它是对现有类似哺乳动物免疫系统结构的功能扩展，用于与癌细胞表面蛋白结合，并阻止可能逃避目前使用的工程化免疫细胞疗法的突变癌症。一种治疗方法是将双肽配体掩蔽物注入患者的血液中，另一种治疗方法是将双肽配体掩蔽物注入局部癌症中，与癌细胞表面蛋白结合。哺乳动物免疫系统长期以来一直使用类似但更复杂的结构，称为五聚蛋白，将各种类型的病原体与免疫细胞物理连接起来，以中和它们。与针对癌症的工程化免疫细胞治疗相比，这种治疗方法具有增加与癌细胞表面蛋白突变结合适应性的潜在优势，并且与针对癌症的工程化免疫细胞治疗相比，尤其是针对突变癌细胞，甚至与极其特异性和昂贵的单克隆抗体治疗或工程化 T 细胞治疗相比，这种治疗方法的潜在治疗成本更低。
